| Status: In progress | |
Treatment of non-metastatic hormone-sensitive prostate cancer at high risk of progression. |
|
Medicine details |
|
| Medicine name | abiraterone acetate (Zytiga®) |
| Formulation | film coated tablets |
| Reference number | OW20 |
| Indication | Non-metastatic hormone-sensitive prostate cancer at high risk of progression |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | One Wales |
| Status | In progress |
| Date of issue | 06/06/2022 |